UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): July 8, 2021

LIXTE BIOTECHNOLOGY HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

161 West Altadena Drive

Altadena, California 91001

(Address of principal executive offices)

(631) 830-7092

(Registrant’s telephone number, including area code)

248 Route 25A, No. 2

East Setauket, New York 11733

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):

Securities registered pursuant to Section 12(b) of the Act:

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter)

Emerging growth company [  ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

On July 8, 2021, the Company held its annual meeting of stockholders (the “Annual Meeting”). The matters voted upon were:

Proposal 1: The election of six director nominees to the Company’s Board of Directors to serve for a one-year term expiring at the 2022 annual meeting of stockholders.

Proposal 2: To approve, in an advisory (non-binding) vote, the fiscal year 2020 executive compensation.

Proposal 3: To approve, in an advisory (non-binding) vote, the frequency of voting on executive compensation.

Proposal 4: To ratify the appointment of Weinberg & Company, P.A. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.

The results of the voting were as follows:

Proposal 1 (election of directors):

Each of the director nominees to the Company’s Board of Directors was elected as follows:

Proposal 2 (executive compensation):

Proposal 3 (frequency of vote):

Proposal 4 (appointment of accounting firm):

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.